Assessment of structural chromosomal instability phenotypes as biomarkers of carboplatin response in triple negative breast cancer: the TNT trial

BACKGROUND: In the TNT trial of triple negative breast cancer (NCT00532727), germline BRCA1/2 mutations were present in 28% of carboplatin responders. We assessed quantitative measures of structural chromosomal instability (CIN) to identify a wider patient subgroup within TNT with preferential benef...

Descripción completa

Detalles Bibliográficos
Autores principales: Sipos, O., Tovey, H., Quist, J., Haider, S., Nowinski, S., Gazinska, P., Kernaghan, S., Toms, C., Maguire, S., Orr, N., Linn, S.C., Owen, J., Gillett, C., Pinder, S.E., Bliss, J.M., Tutt, A., Cheang, M.C.U., Grigoriadis, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7784666/
https://www.ncbi.nlm.nih.gov/pubmed/33098992
http://dx.doi.org/10.1016/j.annonc.2020.10.475

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7784666/
https://www.ncbi.nlm.nih.gov/pubmed/33098992
http://dx.doi.org/10.1016/j.annonc.2020.10.475

Ejemplares similares